Puma Biotechnology
Puma Biotechnology Inc. (NYSE: PBYI) shareholders vote against PPD founder Fred Eshelman - Triangle Business Journal
DFAN14A
Puma Biotechnology, Inc. IPO Investment Prospectus S-1
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Why Puma Biotechnology Is Soaring Today | Nasdaq
PUMA_BIOTECHNOLOGY
PBYI Stock Forecast, Price & News (Puma Biotechnology)
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
Breakeven On The Horizon For Puma Biotechnology, Inc. (NASDAQ:PBYI) | Nasdaq
Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Genomes Reflect Inbreeding, Highlight Rescue Options
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
From summer lull to biotech's record-breaking month | Evaluate
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate
